Newron

Newron Licenses Schizophrenia Treatment to EA Pharma

Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.

News

Newron Agrees Parkinson's Drug Deal with Zambon

Top-Feature

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Newron Pharmaceuticals SpA